Cell death and cancer therapy.
Successful cancer therapy requires the selective killing of cancer cells. Many molecular components of the pathways that lead to cell death have recently been identified and a number of these, including p53, Apaf-1, and members of the inhibitor of apoptosis protein and Bcl-2 gene families, have been found to be altered or disregulated in many cancers. These recent advances and the ongoing elucidation of how these pathways work is providing clues as to how therapeutically resistant cancers might be attacked.
Bunz
F
F
Radiation Biology Program, The Johns Hopkins Oncology Center, The Johns Hopkins School of Medicine, Baltimore, MD 21231, USA. bunzfre@welch.jhu.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D016923:Cell Death / Q000235:genetics / Q000502:physiology*; D019254:Genes, bcl-2 / Q000235:genetics; D016158:Genes, p53 / Q000235:genetics; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*
D000970:Antineoplastic Agents